If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

IN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: N/A

Insider Buying (Last 12 Months): C$15,965.89

Insider Selling (Last 12 Months): C$0.00

InMed Pharmaceuticals Insider Trading History Chart

InMed Pharmaceuticals Share Price & Price History

C^$0.00

+0.30 (1.20%)

As of 05/7/2021 01:00 AM ET

Days: 30 | 90 | 365

5 Game-Changing Cheap Stocks

From Daily Market Alerts | Ad

These 5 stocks have the potential to outperform the overall market over time because of their future potential.

They are well-positioned to deliver a high upside to investors over the next 12 to 18 months.

Discover all the details - including name and ticker symbol - here.

>>>

InMed Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/13/2022	Eric Ashley Adams	Director	Buy	8,560	C$1.07	C$9,167.76	44,843
1/24/2022	Bruce Colwill	Senior Officer	Buy	5,000	C$1.36	C$6,798.13	11,515
9/28/2021	Eric Ashley Adams	Director	Buy	11,400	C$2.31	C$26,379.14	27,483
11/28/2019	Eric Ashley Adams	Director	Buy	100,000	C$0.25	C$25,000.00	530,725
10/31/2019	Alexandra Diane Janet Mancini	Senior Officer	Buy	8,500	C$0.25	C$2,097.80	166,500
10/28/2019	Alexandra Diane Janet Mancini	Senior Officer	Buy	10,000	C$0.26	C$2,600.00	158,000
10/24/2019	Alexandra Diane Janet Mancini	Senior Officer	Buy	1,500	C$0.26	C$390.00	148,000
10/21/2019	Alexandra Diane Janet Mancini	Senior Officer	Buy	2,500	C$0.27	C$675.00	136,500
10/17/2019	Alexandra Diane Janet Mancini	Senior Officer	Buy	14,000	C$0.27	C$3,710.00	134,000
10/15/2019	Alexandra Diane Janet Mancini	Senior Officer	Buy	10,000	C$0.28	C$2,800.00	110,000
10/11/2019	Alexandra Diane Janet Mancini	Senior Officer	Buy	15,000	C$0.26	C$3,825.00	100,000

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

SEC Filings (Institutional Ownership Changes) for InMed Pharmaceuticals (TSE:IN)

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Today's Range

Now: N/A

50 Day Range

MA: C$4.19

C$4.19

52 Week Range

Now: N/A

Volume

17,035 shs

Average Volume

29,552 shs

Market Capitalization

C$33.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of InMed Pharmaceuticals?: InMed Pharmaceuticals' top insider shareholders include:
Eric Ashley Adams (Director)
Bruce Colwill (Senior Officer)
Learn More about top insider investors at InMed Pharmaceuticals.